Department of Surgical Oncology, Cancer Centre, Copernicus Memorial Hospital, Lodz, Poland.
Arch Med Sci. 2012 May 9;8(2):310-5. doi: 10.5114/aoms.2012.28559.
Pathologic complete response (pCR) after neoadjuvant systemic treatment for inoperable locally advanced breast cancer is defined as complete microscopic disappearance of invasive cancer in both the breast and axilla in the postoperative specimen. The aim of the study was to characterize the groups of younger (≤ 40 years old) and older (≥ 70 years old) breast cancer patients who achieved a pCR.
One hundred thirty-eight consecutive patients aged between 30 and 78 years with locally advanced breast cancer, operated on after neoadjuvant systemic treatment between November 2007 and June 2010, were analyzed. In this group 9 women (6.5%) were 40 years of age or younger, and 12 patients (8.7%) were 70 years of age or older.
In the younger group, pCR was achieved in 1 patient with triple negative, invasive ductal breast cancer, G3, BRCA 1 mutation, treated with cisplatin. A near pCR was achieved in 2 other patients, with triple negative, invasive ductal breast cancer, G3, treated with AT. The pCR in the breast was found in a HER2 positive patient. In older patients, pCR was achieved in 2 patients with triple negative, invasive ductal breast cancer, G3, treated with AT or FEC. Pathologic complete response in the axilla was achieved in 1 patient with triple negative, ductal carcinoma. The pCR rates were significantly higher in triple negative breast cancer in both groups (p = 0.047 and p = 0.018, respectively).
Pathologic complete response was significantly associated with receptor- based subtypes in both young and old women.
新辅助全身治疗后不可手术的局部晚期乳腺癌的病理完全缓解（pCR）定义为术后标本中乳腺和腋窝内浸润性癌完全消失。本研究的目的是描述达到 pCR 的年轻（≤40 岁）和老年（≥70 岁）乳腺癌患者的特征。
分析了 2007 年 11 月至 2010 年 6 月间接受新辅助全身治疗后手术的 138 例年龄在 30 至 78 岁之间的局部晚期乳腺癌连续患者。该组中 9 名女性（6.5%）年龄为 40 岁或以下，12 名患者（8.7%）年龄为 70 岁或以上。
在年轻组中，1 例三阴性、浸润性导管乳腺癌、G3、BRCA1 突变患者接受顺铂治疗达到 pCR。另外 2 例三阴性、浸润性导管乳腺癌、G3 患者接受 AT 治疗达到接近 pCR。HER2 阳性患者的乳腺 pCR。在老年患者中，2 例三阴性、浸润性导管乳腺癌、G3 患者接受 AT 或 FEC 治疗达到 pCR。1 例三阴性、导管癌患者腋窝 pCR。两组三阴性乳腺癌的 pCR 率均显著升高（分别为 p=0.047 和 p=0.018）。
在年轻和老年女性中，pCR 与受体为基础的亚型显著相关。
